Microarray analyses of peripheral whole blood cells from ulcerative colitis patients: Effects of leukocytapheresis

Kobayashi,Teppei; Mitsuyama,Keiichi; Yamasaki,Hiroshi; Masuda,Junya; Takedatsu,Hidetoshi; Kuwaki,Kotaro; Yoshioka,Shinichiro; Nagayama,Koji; Sata,Michio

doi:10.3892/ijmm.2013.1270

Microarray analyses of peripheral whole blood cells from ulcerative colitis patients: Effects of leukocytapheresis

Authors:
- Teppei Kobayashi
- Keiichi Mitsuyama
- Hiroshi Yamasaki
- Junya Masuda
- Hidetoshi Takedatsu
- Kotaro Kuwaki
- Shinichiro Yoshioka
- Koji Nagayama
- Michio Sata
View Affiliations

Affiliations: Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan
Published online on: February 6, 2013 https://doi.org/10.3892/ijmm.2013.1270
Pages: 789-796

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Complementary DNA microarray technology allows the simultaneous analysis of the expression of hundreds to thousands of genes. We applied this technique to clarify the molecular mechanisms underlying the therapeutic effects of leukocytapheresis (LCAP) therapy in patients with ulcerative colitis (UC). A 776-gene microarray analysis was performed using whole blood cells from six normal subjects and six patients with active UC who had undergone filtration LCAP. Widespread gene upregulation was observed in patients with UC, compared with normal subjects. After LCAP, genes with proinflammatory actions, such as CD97, CD74, human leukocyte antigen-DRβ1 and -DP light chain, were downregulated, while genes responsible for antimicrobial actions, such as neutrophil gelatinase-associated lipocalin, and acute phase reactions, such as haptoglobin α1S and α1-acid glycoprotein, were upregulated. In conclusion, we identified several genes expressed in the whole blood cells of UC patients as well as the transcriptional events following LCAP. Following LCAP, the gene profile shifted toward a pattern indicating disease improvement. These results suggest a basis for the molecular mechanisms leading to the therapeutic effects of LCAP and also indicate new therapeutic targets, providing important prognostic information.

View Figures

View References

1	Podolsky DK: Inflammatory bowel disease. N Engl J Med. 347:417–429. 2002. View Article : Google Scholar
2	Bamias G, Nyce MR, De La Rue SA and Cominelli F; American College of Physicians; American Physiological Society. New concepts in the pathophysiology of inflammatory bowel disease. Ann Intern Med. 143:895–904. 2005. View Article : Google Scholar : PubMed/NCBI
3	Targan SR and Karp LC: Defects in mucosal immunity leading to ulcerative colitis. Immunol Rev. 206:296–305. 2005. View Article : Google Scholar : PubMed/NCBI
4	Grimm MC, Pullman WE, Bennett GM, Sullivan PJ, Pavli P and Doe WF: Direct evidence of monocyte recruitment to inflammatory bowel disease mucosa. J Gastroenterol Hepatol. 10:387–395. 1995. View Article : Google Scholar : PubMed/NCBI
5	Rugtveit J, Brandtzaeg P, Halstensen TS, Fausa O and Scott H: Increased macrophage subset in inflammatory bowel disease: apparent recruitment from peripheral blood monocytes. Gut. 35:669–674. 1994. View Article : Google Scholar : PubMed/NCBI
6	Kondoh T, Hidaka Y, Katoh H, Inoue N and Saito S: Evaluation of a filtration lymphocytapheresis (LCP) device for use in the treatment of patients with rheumatoid arthritis. Artif Organs. 15:180–188. 1991. View Article : Google Scholar : PubMed/NCBI
7	Sawada K, Ohnishi K, Fukui S, et al: Leukocytapheresis therapy, performed with leukocyte removal filter, for inflammatory bowel disease. J Gastroenterol. 30:322–329. 1995. View Article : Google Scholar : PubMed/NCBI
8	Ortolano GA, Capetandes A and Wenz B: A review of leukofiltration therapy for decreasing the morbidity associated with cardiopulmonary bypass and acute inflammatory bowel disease. Ther Apher. 6:119–129. 2002. View Article : Google Scholar : PubMed/NCBI
9	Sawada K, Muto T, Shimoyama T, et al: Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column. Curr Pharm Des. 9:307–321. 2003. View Article : Google Scholar : PubMed/NCBI
10	Yajima T, Takaishi H, Kanai T, et al: Predictive factors of response to leukocytapheresis therapy for ulcerative colitis. Ther Apher. 2:115–119. 1998. View Article : Google Scholar : PubMed/NCBI
11	Sasaki M, Tsujikawa T, Fujiyama Y and Bamba T: Leukocytapheresis therapy for severe ulcerative colitis. Ther Apher. 2:101–104. 1998. View Article : Google Scholar
12	Kosaka T, Sawada K, Ohnishi K, et al: Effect of leukocytapheresis therapy using a leukocyte removal filter in Crohn's disease. Intern Med. 38:102–111. 1999. View Article : Google Scholar
13	Hidaka T, Suzuki K, Matsuki Y, et al: Filtration leukocytapheresis therapy in rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 42:431–437. 1999. View Article : Google Scholar : PubMed/NCBI
14	Ueki Y, Yamasaki S, Kanamoto Y, et al: Evaluation of filtration leucocytapheresis for use in the treatment of patients with rheumatoid arthritis. Rheumatology. 39:165–171. 2000. View Article : Google Scholar : PubMed/NCBI
15	Furuta T, Hotta O, Yusa N, Horigome I, Chiba S and Taguma Y: Lymphocytapheresis to treat rapidly progressive glomerulonephritis: a randomised comparison with steroid-pulse treatment. Lancet. 352:203–204. 1998. View Article : Google Scholar : PubMed/NCBI
16	Dieckgraefe BK, Stenson WF, Korzenik JR, Swanson PE and Harrington CA: Analysis of mucosal gene expression in inflammatory bowel disease by parallel oligonucleotide arrays. Physiol Genomics. 4:1–11. 2000.PubMed/NCBI
17	Lawrance IC, Fiocchi C and Chakravarti S: Ulcerative colitis and Crohn's disease: distinctive gene expression profiles and novel susceptibility candidate genes. Hum Mol Genet. 10:445–456. 2001.
18	Heller RA, Schena M, Chai A, et al: Discovery and analysis of inflammatory disease-related genes using cDNA microarrays. Proc Natl Acad Sci USA. 94:2150–2155. 1997. View Article : Google Scholar : PubMed/NCBI
19	Truelove SC and Witts LJ: Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 2:1041–1048. 1955. View Article : Google Scholar : PubMed/NCBI
20	Nagase K, Sawada K, Ohnishi K, Egashira A, Ohkusu K and Shimoyama T: Complications of leukocytapheresis. Ther Apher. 2:120–124. 1998. View Article : Google Scholar
21	Hashimoto S, Suzuki T, Dong HY, Yamazaki N and Matsushima K: Serial analysis of gene expression in human monocytes and macrophages. Blood. 94:837–844. 1999.PubMed/NCBI
22	Hashimoto S, Suzuki T, Dong HY, Nagai S, Yamazaki N and Matsushima K: Serial analysis of gene expression in human monocyte-derived dendritic cells. Blood. 94:845–852. 1999.PubMed/NCBI
23	Hashimoto SI, Suzuki T, Nagai S, Yamashita T, Toyoda N and Matsushima K: Identification of genes specifically expressed in human activated and mature dendritic cells through serial analysis of gene expression. Blood. 96:2206–2214. 2000.
24	Nagai S, Hashimoto S, Yamashita T, et al: Comprehensive gene expression profile of human activated T(h)1- and T(h)2-polarized cells. Int Immunol. 13:367–376. 2001. View Article : Google Scholar : PubMed/NCBI
25	Khodursky AB, Peter BJ, Cozzarelli NR, Botstein D, Brown PO and Yanofsky C: DNA microarray analysis of gene expression in response to physiological and genetic changes that affect tryptophan metabolism in Escherichia coli. Proc Natl Acad Sci USA. 97:12170–12175. 2000. View Article : Google Scholar : PubMed/NCBI
26	Yang YH, Dudoit S, Luu P, et al: Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res. 30:e152002. View Article : Google Scholar : PubMed/NCBI
27	Baechler EC, Batliwalla FM, Karypis G, et al: Expression levels for many genes in human peripheral blood cells are highly sensitive to ex vivo incubation. Genes Immun. 5:347–353. 2004. View Article : Google Scholar : PubMed/NCBI
28	Rauschmayr T, Groves RW and Kupper TS: Keratinocyte expression of the type 2 interleukin 1 receptor mediates local and specific inhibition of interleukin 1-mediated inflammation. Proc Natl Acad Sci USA. 94:5814–5819. 1997. View Article : Google Scholar : PubMed/NCBI
29	Odink K, Cerletti N, Bruggen J, et al: Two calcium-binding proteins in infiltrate macrophages of rheumatoid arthritis. Nature. 330:80–82. 1987. View Article : Google Scholar : PubMed/NCBI
30	Cui XF, Li HH, Goradia TM, et al: Single-sperm typing: determination of genetic distance between the G gamma-globin and parathyroid hormone loci by using the polymerase chain reaction and allele-specific oligomers. Proc Natl Acad Sci USA. 86:9389–9393. 1989. View Article : Google Scholar
31	Robertson MW, Albrandt K, Keller D and Liu FT: Human IgE-binding protein: a soluble lectin exhibiting a highly conserved interspecies sequence and differential recognition of IgE glycoforms. Biochemistry. 29:8093–8100. 1990. View Article : Google Scholar
32	Takahashi N, Ueda S, Obata M, Nikaido T, Nakai S and Honjo T: Structure of human immunoglobulin gamma genes: implications for evolution of a gene family. Cell. 29:671–679. 1982. View Article : Google Scholar : PubMed/NCBI
33	Mitsuyama K, Suzuki A, Matsumoto S, et al: Diminished cytokine signalling against bacterial components in mononuclear leucocytes from ulcerative colitis patients after leukocytapheresis. Clin Exp Immunol. 141:130–140. 2005. View Article : Google Scholar
34	Andoh A, Ogawa A, Kitamura K, et al: Suppression of interleukin-1beta- and tumor necrosis factor-alpha-induced inflammatory responses by leukocytapheresis therapy in patients with ulcerative colitis. J Gastroenterol. 39:1150–1157. 2004. View Article : Google Scholar : PubMed/NCBI
35	Noguchi M, Hiwatashi N, Hayakawa T and Toyota T: Leukocyte removal filter-passed lymphocytes produce large amounts of interleukin-4 in immunotherapy for inflammatory bowel disease: role of bystander suppression. Ther Apher. 2:109–114. 1998. View Article : Google Scholar
36	Gray JX, Haino M, Roth MJ, et al: CD97 is a processed, seven-transmembrane, heterodimeric receptor associated with inflammation. J Immunol. 157:5438–5447. 1996.PubMed/NCBI
37	Leemans JC, te Velde AA, Florquin S, et al: The epidermal growth factor-seven transmembrane (EGF-TM7) receptor CD97 is required for neutrophil migration and host defense. J Immunol. 172:1125–1131. 2004. View Article : Google Scholar : PubMed/NCBI
38	Leng L, Metz CN, Fang Y, et al: MIF signal transduction initiated by binding to CD74. J Exp Med. 197:1467–1476. 2003. View Article : Google Scholar : PubMed/NCBI
39	Ohkawara T, Nishihira J, Takeda H, et al: Amelioration of dextran sulfate sodium-induced colitis by anti-macrophage migration inhibitory factor antibody in mice. Gastroenterology. 123:256–270. 2002. View Article : Google Scholar : PubMed/NCBI
40	Salomon P, Pizzimenti A, Panja A, Reisman A and Mayer L: The expression and regulation of class II antigens in normal and inflammatory bowel disease peripheral blood monocytes and intestinal epithelium. Autoimmunity. 9:141–149. 1991. View Article : Google Scholar : PubMed/NCBI
41	Kjeldsen L, Johnsen AH, Sengelov H and Borregaard N: Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem. 268:10425–10432. 1993.PubMed/NCBI
42	Nielsen BS, Borregaard N, Bundgaard JR, Timshel S, Sehested M and Kjeldsen L: Induction of NGAL synthesis in epithelial cells of human colorectal neoplasia and inflammatory bowel diseases. Gut. 38:414–420. 1996. View Article : Google Scholar : PubMed/NCBI
43	Cid MC, Grant DS, Hoffman GS, Auerbach R, Fauci AS and Kleinman HK: Identification of haptoglobin as an angiogenic factor in sera from patients with systemic vasculitis. J Clin Invest. 91:977–985. 1993. View Article : Google Scholar : PubMed/NCBI
44	Laine E, Couderc R, Roch-Arveiller M, Vasson MP, Giroud JP and Raichvarg D: Modulation of human polymorphonuclear neutrophil functions by alpha 1-acid glycoprotein. Inflammation. 14:1–9. 1990. View Article : Google Scholar : PubMed/NCBI
45	Wispe JR, Clark JC, Burhans MS, Kropp KE, Korfhagen TR and Whitsett JA: Synthesis and processing of the precursor for human mangano-superoxide dismutase. Biochim Biophys Acta. 994:30–36. 1989. View Article : Google Scholar : PubMed/NCBI
46	Russell L and Forsdyke DR: A human putative lymphocyte G0/G1 switch gene containing a CpG-rich island encodes a small basic protein with the potential to be phosphorylated. DNA Cell Biol. 10:581–591. 1991. View Article : Google Scholar : PubMed/NCBI
47	Warburton G, Nares S, Angelov N, Brahim JS, Dionne RA and Wahl SM: Transcriptional events in a clinical model of oral mucosal tissue injury and repair. Wound Repair Regen. 13:19–26. 2005. View Article : Google Scholar : PubMed/NCBI
48	Pirila E, Ramamurthy NS, Sorsa T, Salo T, Hietanen J and Maisi P: Gelatinase A (MMP-2), collagenase-2 (MMP-8), and laminin-5 gamma2-chain expression in murine inflammatory bowel disease (ulcerative colitis). Dig Dis Sci. 48:93–98. 2003. View Article : Google Scholar : PubMed/NCBI
49	Yamaji K, Yang K, Tsuda H and Hashimoto H: Fluctuations in the peripheral blood leukocyte and platelet counts in leukocytapheresis in healthy volunteers. Ther Apher. 6:402–412. 2002. View Article : Google Scholar : PubMed/NCBI
50	Sawada K, Ohnishi K, Kosaka T, et al: Leukocytapheresis with leukocyte removal filter as new therapy for ulcerative colitis. Ther Apher. 1:207–211. 1997. View Article : Google Scholar : PubMed/NCBI
51	Danese S: New therapies for inflammatory bowel disease: from the bench to the bedside. Gut. 61:918–932. 2012. View Article : Google Scholar : PubMed/NCBI
52	Rutgeerts P, Vermeire S and Van Assche G: Biological therapies for inflammatory bowel diseases. Gastroenterology. 136:1182–1197. 2009. View Article : Google Scholar : PubMed/NCBI
53	Mitsuyama K and Sata M: Gut microflora: a new target for therapeutic approaches in inflammatory bowel disease. Expert Opin Ther Targets. 12:301–312. 2008. View Article : Google Scholar : PubMed/NCBI
54	Duijvestein M, van den Brink GR and Hommes DW: Stem cells as potential novel therapeutic strategy for inflammatory bowel disease. J Crohns Colitis. 2:99–106. 2008. View Article : Google Scholar : PubMed/NCBI